These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 30409518)

  • 21. Excess of nicastrin in brain results in heterozygosity having no effect on endogenous APP processing and amyloid peptide levels in vivo.
    Brijbassi S; Amtul Z; Newbigging S; Westaway D; St George-Hyslop P; Rozmahel RF
    Neurobiol Dis; 2007 Feb; 25(2):291-6. PubMed ID: 17071095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secretases-related miRNAs in Alzheimer's disease: new approach for biomarker discovery.
    Hajjari SN; Mehdizadeh M; Sadigh-Eteghad S; Shanehbandi D; Teimourian S; Baradaran B
    Neurol Sci; 2017 Nov; 38(11):1921-1926. PubMed ID: 28791490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel γ-secretase modulators: a review of patents from 2008 to 2010.
    Pettersson M; Kauffman GW; am Ende CW; Patel NC; Stiff C; Tran TP; Johnson DS
    Expert Opin Ther Pat; 2011 Feb; 21(2):205-26. PubMed ID: 21231889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of sulindac sulfide on the membrane architecture and the activity of gamma-secretase.
    Gamerdinger M; Clement AB; Behl C
    Neuropharmacology; 2008 May; 54(6):998-1005. PubMed ID: 18359496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. γ-Secretase as a target for Alzheimer's disease.
    Wolfe MS
    Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
    Wiley JC; Hudson M; Kanning KC; Schecterson LC; Bothwell M
    J Neurochem; 2005 Sep; 94(5):1189-201. PubMed ID: 15992373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence For and Against a Pathogenic Role of Reduced γ-Secretase Activity in Familial Alzheimer's Disease.
    Jayne T; Newman M; Verdile G; Sutherland G; Münch G; Musgrave I; Moussavi Nik SH; Lardelli M
    J Alzheimers Dis; 2016 Apr; 52(3):781-99. PubMed ID: 27060961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
    Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N
    Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Alzheimer's disease-associated gamma-secretase complex: functional domains in the presenilin 1 protein.
    Laudon H; Winblad B; Näslund J
    Physiol Behav; 2007 Sep; 92(1-2):115-20. PubMed ID: 17588625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SAR-studies of γ-secretase modulators with PPARγ-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease.
    Flesch D; Ness J; Lamers C; Dehm F; Popella S; Steri R; Ogorek I; Hieke M; Dannhardt G; Werz O; Weggen S; Schubert-Zsilavecz M
    Bioorg Med Chem Lett; 2015 Feb; 25(4):841-6. PubMed ID: 25575659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated gamma-secretase.
    Narlawar R; Pérez Revuelta BI; Baumann K; Schubenel R; Haass C; Steiner H; Schmidt B
    Bioorg Med Chem Lett; 2007 Jan; 17(1):176-82. PubMed ID: 17035010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of new Presenilin-1 phosphosites: implication for γ-secretase activity and Aβ production.
    Matz A; Halamoda-Kenzaoui B; Hamelin R; Mosser S; Alattia JR; Dimitrov M; Moniatte M; Fraering PC
    J Neurochem; 2015 May; 133(3):409-21. PubMed ID: 25458374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
    Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
    Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular dynamics simulation study reveals potential substrate entry path into γ-secretase/presenilin-1.
    Kong R; Chang S; Xia W; Wong ST
    J Struct Biol; 2015 Aug; 191(2):120-9. PubMed ID: 26142917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific Inhibition of β-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein.
    Ben Halima S; Mishra S; Raja KMP; Willem M; Baici A; Simons K; Brüstle O; Koch P; Haass C; Caflisch A; Rajendran L
    Cell Rep; 2016 Mar; 14(9):2127-2141. PubMed ID: 26923602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
    Pollack SJ; Lewis H
    Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RAGE mediates Aβ accumulation in a mouse model of Alzheimer's disease via modulation of β- and γ-secretase activity.
    Fang F; Yu Q; Arancio O; Chen D; Gore SS; Yan SS; Yan SF
    Hum Mol Genet; 2018 Mar; 27(6):1002-1014. PubMed ID: 29329433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.